SCHEMBL6880733

SCHEMBL6880733

CC(C)(C)[Si](OC[C@@H]1C=C[C@H](n2cc(C#N)c3c(N)ncnc32)O1)(c1ccccc1)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADK P55263 3/20 0.44
DOT1L Q8TEK3 3/20 0.38
PRMT5 O14744 2/20 0.38
PRMT3 O60678 1/20 0.38
DNMT1 P26358 1/20 0.38
EHMT2 Q96KQ7 1/20 0.38
RNMT O43148 1/20 0.36
LRRK2 Q5S007 3/20 0.35
DUT P33316 1/20 0.35
BCHE P06276 1/20 0.34
FLT3 P36888 2/20 0.33
METTL3 Q86U44 1/20 0.33
WDR77 Q9BQA1 1/20 0.33
SRC P12931 3/20 0.33
KDR P35968 2/20 0.33
EGFR P00533 1/20 0.33
TEK Q02763 1/20 0.33
DAPK3 O43293 1/20 0.32
MAP4K4 O95819 1/20 0.32
PAK4 O96013 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31022850 0.78 ADK (0.41) ADKDOT1LPRMT5PRMT3DNMT1
SCHEMBL27195436 0.78 ADK (0.41) ADKDOT1LPRMT5PRMT3DNMT1
SCHEMBL7214567 0.78 ADK (0.46) ADKDOT1LPRMT5PRMT3DNMT1
SCHEMBL6868897 0.78 ADK (0.43) ADKDOT1LPRMT5PRMT3DNMT1
SCHEMBL6875297 0.77 ADK (0.55) ADKDOT1LPRMT5PRMT3DNMT1
SCHEMBL9689038 0.74 BCHE (0.39) DUTBCHEADORA1
SCHEMBL20938198 0.73 ADK (0.46) ADKPRMT5DUTMETTL3
SCHEMBL11899655 0.73 DUT (0.42) DUTBCHE
SCHEMBL14598203 0.73 ADK (0.46) ADKDOT1LPRMT5RNMTLRRK2
SCHEMBL30849550 0.72 HASPIN (0.35) ADKDOT1LPRMT5RNMTWDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831069-B2 Having substituents at the C4' and C5' positions of the ribofuranose moiety; anticancer and immunomodulating effects at reduced cytotoxicity; treating autoimmune diseases, cancer, dermatitis RIBAPHARM INC. 2004-12-14 US disclosed
US-20020035077-A1 Pyrrolo[2,3-d]pyrimidine nucleoside analogs CEQUENT PHARMACEUTICALS, INC. 2002-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035077-A1 Pyrrolo[2,3-d]pyrimidine nucleoside analogs TYMP, DPYD, TYMS ADK 662/4885DOT1L 3621/4885PRMT5 864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.